• For US Healthcare Professionals
  • For Patients and Caregivers
A A A

Resource Center >

My Patient Solutions®
  • Patients and Caregivers
  • Learn About Our Services
    • KADCYLA Coverage
    • Reimbursement
    • KADCYLA Distribution
    • My Patient Solutions
  • Find Patient Assistance
    • Referrals to Genentech Co-pay Cards
    • Referrals to Independent Co-pay Assistance Foundations
    • Referrals to the Genentech Patient Foundation
  • Forms & Documents

Resource Center >

My Patient Solutions®
  • ACTEMRA® (tocilizumab)‎
  • ALECENSA® (alectinib)
  • AVASTIN® (bevacizumab)
  • COTELLIC® (cobimetinib)
  • ERIVEDGE® (vismodegib)
  • ESBRIET® (pirfenidone)
  • GAZYVA® (obinutuzumab)
  • HEMLIBRA® (emicizumab-kxwh)
  • HERCEPTIN® (trastuzumab)
  • HERCEPTIN HYLECTA™ (trastuzumab and hyaluronidase-oysk)
  • KADCYLA® (ado-trastuzumab emtansine)
  • LUCENTIS® (ranibizumab injection)
  • OCREVUS® (ocrelizumab)
  • PERJETA® (pertuzumab)
  • POLIVY™ (polatuzumab vedotin-piiq)
  • PULMOZYME® (dornase alfa) Inhalation Solution
  • RITUXAN® (rituximab)
  • RITUXAN HYCELA® (rituximab/hyaluronidase human)
  • ROZLYTREK™ (entrectinib)
  • TARCEVA® (erlotinib)
  • TECENTRIQ® (atezolizumab)
  • VENCLEXTA® (venetoclax tablets)
  • XOLAIR® (omalizumab) for subcutaneous use
  • ZELBORAF® (vemurafenib)
  • BIOONCOLOGY
  • RHEUMATOLOGY

Please select a treatment to continue

  • ACTEMRA® (tocilizumab)‎
  • ALECENSA® (alectinib)
  • AVASTIN® (bevacizumab)
  • COTELLIC® (cobimetinib)
  • ERIVEDGE® (vismodegib)
  • ESBRIET® (pirfenidone)
  • GAZYVA® (obinutuzumab)
  • HEMLIBRA® (emicizumab-kxwh)
  • HERCEPTIN® (trastuzumab)
  • HERCEPTIN HYLECTA™ (trastuzumab and hyaluronidase-oysk)
  • KADCYLA® (ado-trastuzumab emtansine)
  • LUCENTIS® (ranibizumab injection)
  • OCREVUS® (ocrelizumab)
  • PERJETA® (pertuzumab)
  • POLIVY™ (polatuzumab vedotin-piiq)
  • PULMOZYME® (dornase alfa) Inhalation Solution
  • RITUXAN® (rituximab)
  • RITUXAN HYCELA® (rituximab/hyaluronidase human)
  • ROZLYTREK™ (entrectinib)
  • TARCEVA® (erlotinib)
  • TECENTRIQ® (atezolizumab)
  • VENCLEXTA® (venetoclax tablets)
  • XOLAIR® (omalizumab) for subcutaneous use
  • ZELBORAF® (vemurafenib)
  • Or Select

  • BIOONCOLOGY
  • RHEUMATOLOGY

Please select a treatment to continue

Select a disease state for Rituxan® (rituximab)

  • RITUXAN® (rituximab) for Rheumatoid Arthritis (RA)
  • RITUXAN® (rituximab) for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
  • RITUXAN® (rituximab) for BioOncology
  • RITUXAN® (rituximab) for Pemphigus Vulgaris (PV)

Site Map

Health Care Professionals

Learn About Our Services
KADCYLA Coverage
Reimbursement
KADCYLA Distribution
My Patient Solutions
Find Patient Assistance
Referrals to Genentech Co-pay Cards
Referrals to Independent Co-pay Assistance Foundations
Referrals to the Genentech Patient Foundation
Forms & Documents

Learn About Treatment With KADCYLA >

Download the forms you need to get started

View KADCYLA Forms and Documents >

Latest Updates

New enrollment forms

Learn More >

 

Genentech Patient Foundation

Learn More >

2019
  • Contact Us
  • Site Map
  • Privacy Policy
  • Terms & Conditions

©[YEAR] Genentech USA, Inc.  All rights reserved.  This site is intended for US residents only.
The Access Solutions logo is a registered trademark of Genentech, Inc.

Link to Third Party Site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel OK

Link to Healthcare Professionals Site

The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.

Cancel OK

Cancel

Your email has been sent!

Thanks for sharing this page.